neuroClues Raises €10M for Parkinson’s Diagnostic Tech
▼ Summary
– neuroClues has developed a portable headset that uses infrared imaging to capture rapid eye movements and AI to extract biomarkers for neurological disorders.
– The device can indicate conditions like Parkinson’s, Alzheimer’s, and multiple sclerosis years before clinical symptoms such as tremors or memory loss appear.
– The company received CE certification for its Class IIa medical device in January 2025, clearing it for use in the European market.
– neuroClues closed a €10 million Series A funding round, bringing its total funding since its 2020 founding to over €22 million.
– The new capital will support commercial expansion, pursuit of FDA clearance targeted for 2026, and further development of the device for clinical use.
A French-Belgian medical technology firm has secured a €10 million Series A investment to advance its portable diagnostic tool for detecting neurological diseases. The company, neuroClues, is developing an AI-powered eye-tracking headset designed to identify conditions like Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis potentially years before overt symptoms emerge. This latest funding round brings the company’s total capital raised since its 2020 founding to over €22 million.
The core technology is a compact, connected headset that captures an extraordinary 800 infrared images per eye per second as a patient follows a moving visual target. Sophisticated artificial intelligence algorithms then analyze this data to extract precise oculomotor biomarkers within minutes. This process provides neurologists with objective, quantifiable measurements that can signal the presence of a neurodegenerative disorder long before clinical signs like tremors or memory loss appear. The device requires no calibration and is intended for seamless use during a standard clinical consultation.
The scientific foundation for using eye movement analysis in neurology is well-established, with research dating back over a century. Despite strong evidence of its clinical relevance, the technique has not seen widespread adoption, historically hindered by hardware that was either prohibitively expensive or lacked sufficient precision. neuroClues aims to bridge this gap by creating an accessible tool for the millions of physicians worldwide who currently rely on subjective, manual assessments.
The diagnostic gap is particularly severe for Parkinson’s disease. Current methods are imperfect, leading to a misdiagnosis rate of one in four patients. Individuals often wait an average of 13 months for a confirmed diagnosis, by which time research suggests they may have lost 50 to 70 percent of their dopamine-producing neurons. With the global population of people living with Parkinson’s projected to double to 13 million by 2040, the need for earlier, more accurate tools is urgent.
The company’s progress is underscored by its recent CE certification as a Class IIa medical device, obtained in January 2025, which authorizes its use in the European market. Its technology is already being integrated into significant clinical research, including the Iceberg cohort study at the Paris Brain Institute, which is investigating biomarkers for early Parkinson’s detection. Preliminary research presented at a major neuroscience conference has suggested the test could identify a preclinical marker for Parkinson’s up to five years before an imaging-confirmed diagnosis.
Founded originally as P3Lab by Antoine Pouppez, Pierre Daye, and Pierre Pouget, the company benefits from the latter two founders’ combined 35 years of neuroscience research expertise. Prior to this Series A, neuroClues had raised capital through a seed round, multiple grants from the European Commission’s EIC Accelerator programme, and a pre-Series A round led by White Fund.
The newly acquired €10 million will be deployed to expand the commercial team, drive market entry in Europe, and pursue a critical FDA clearance targeted for 2026 in the United States. The company maintains its headquarters and manufacturing base in Louvain-la-Neuve, Belgium, with an additional office located at the iPEPS incubator within Paris’s La Salpêtrière Hospital.
(Source: The Next Web)